The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents (Q34112975)

31 July 2017

1 reference

title

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents (English)

1 reference

31 July 2017

Rowinsky EK

1

1 reference

31 July 2017

1 January 2000

1 reference

31 July 2017

1 reference

31 July 2017

60 Suppl 1

1 reference

31 July 2017

1-14; discussion 41-2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060001-00001

31 July 2017

0 references

cites work

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

1 reference

12 December 2020

Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture

1 reference

12 December 2020

Rationale for the use of alternating non-cross-resistant chemotherapy.

1 reference

12 December 2020

Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells

1 reference

12 December 2020

Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821.

1 reference

12 December 2020

Laboratory models: some historical perspective.

1 reference

12 December 2020

A Gompertzian model of human breast cancer growth.

1 reference

12 December 2020

Epidermal growth factor receptor family and chemosensitization

1 reference

12 December 2020

The Norton-Simon hypothesis revisited

1 reference

12 December 2020

Clinical evaluation of biologically targeted drugs: obstacles and opportunities

1 reference

12 December 2020

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Conventional cancer therapy: promise broken or promise delayed?

1 reference

12 December 2020

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

1 reference

12 December 2020

Kinetic parameters and growth curves for experimental tumor systems

1 reference

12 December 2020

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies

1 reference

12 December 2020

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

12 December 2020

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

1 reference

12 December 2020

The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation

1 reference

12 December 2020

New molecular targets for cancer therapy.

1 reference

12 December 2020

Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.

1 reference

12 December 2020

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

1 reference

12 December 2020

Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.

1 reference

12 December 2020

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

1 reference

12 December 2020

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

1 reference

12 December 2020

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture

1 reference

12 December 2020

Growth Curve of an Experimental Solid Tumor Following Radiotherapy

1 reference

12 December 2020

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

1 reference

12 December 2020

2-[C-11]thymidine imaging of malignant brain tumors.

1 reference

12 December 2020

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

12 December 2020

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

12 December 2020

The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts

1 reference

12 December 2020

Patient noncompliance with self-administered chemotherapy

1 reference

12 December 2020

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

12 December 2020

The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

1 reference

12 December 2020

Variance and sample size calculations in quality-of-life--adjusted survival analysis (Q-TWiST).

1 reference

12 December 2020

Patient compliance with oral chemotherapy as assessed by a novel electronic technique

1 reference

12 December 2020

Pharmaceutical research in molecular oncology

1 reference

12 December 2020

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

12 December 2020

Compliance with oral drug therapy in patients with hematologic malignancy.

1 reference

12 December 2020

Development of target-based antineoplastic agents

1 reference

12 December 2020

Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.

1 reference

12 December 2020

The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy

1 reference

12 December 2020

Dose-response is alive and well

1 reference

12 December 2020

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

12 December 2020

Comparison of potential markers of farnesyltransferase inhibition

1 reference

12 December 2020

Randomized discontinuation trials: Utility and efficiency

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

12 December 2020

The promise of molecular oncology.

1 reference

12 December 2020

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

1 reference

12 December 2020

10.2165/00003495-200060001-00001

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

11129167